Cochlear Limited (ASX: COH), a manufacturer of implantable hearing solutions, announced the US Food and Drug Administration’s (FDA) approval of the new Cochlear™ Nucleus® Profile™ Plus Series Cochlear Implant and the Nucleus 7 Sound Processor’s new built-in connectivity featuring direct streaming with compatible Android™ smartphones.

The Nucleus Profile Plus Implant is designed for safe access to Magnetic Resonance Imaging (MRI) scans today and in the future. With the Nucleus Profile Plus Implant, cochlear implant recipients are said to have “easier access to 1.5 and 3.0 Tesla (T) MRI scans” without the need to remove the internal magnet or use a head wrap.1 The new implant is built off Cochlear’s Nucleus Profile Series Implant, which maintains an accessible magnet if removal is ever required.

Nucleus Profile Plus Series Cochlear Implant

Nucleus Profile Plus Series Cochlear Implant

Cochlear was reportedly the “first manufacturer” to introduce an accessible magnet feature to cochlear implants in 1997, allowing the magnet to be removed if required in a simple outpatient procedure before the MRI takes place. The magnet will continue to provide cochlear implant recipients with lifetime access to MRI if their healthcare needs or imaging technology changes over time.

The Nucleus Profile Plus Implant is built on Cochlear’s cochlear implant reliability record of the Profile Implant and the entire Cochlear Nucleus implant portfolio.2-4 The Nucleus Profile Plus Implant also includes a thin design,5 helping to provide cochlear implant recipients the potential of a better cosmetic outcome and less time in surgery.

“For more than two decades, Cochlear has been pleased to provide Nucleus Cochlear Implant recipients with access to MRIs,” said Tony Manna, President, Cochlear Americas. “Now with the approval of the Nucleus Profile Plus Implant, we are able to provide our cochlear implant recipients MRI access without the need to remove the internal magnet or needing a head wrap at 1.5 and 3.0 T, improving the experience for both healthcare professionals and their patients. We are delivering this new innovation without sacrificing our longstanding cochlear implant reliability track record, our thin implant design, and the easy to access magnet that ensures our recipients have continued MRI access now and in the future.”

With FDA approval, as well as Health Canada’s approval, of the Nucleus 7 Sound Processor’s expanded connectivity features, Cochlear will also reportedly be “the first cochlear implant manufacturer” to enable access of direct audio streaming from Android devices to its cochlear implant sound processor without any intermediary device or attachments needed to be added to the sound processor. This approval allows Nucleus 7 recipients the ability to connect to compatible Apple® and Android devices without compromising on size, weight,6 or battery life7 of the sound processor.* Access to direct Android streaming between the Nucleus 7 Sound Processor and a compatible Android phone is dependent upon Android phone manufacturers implementing Google’s Audio Streaming for Hearing Aids (ASHA) protocol into future operating system updates for their handsets.

Since the Nucleus 7 Sound Processor was first launched in 2017 as “the world’s first Made for iPhone cochlear implant sound processor8 ” and the announcement of the Nucleus Smart App compatibility with Android devices in 2018, Cochlear has continued to work to extend the benefits of its industry-leading technology to Android smartphone users as the technology has come available.*

Nucleus 7 Sound Processor

Nucleus 7 Sound Processor

“When a person chooses a cochlear implant, it begins a partnership between them and the cochlear implant company for the rest of their life. As the most chosen cochlear implant manufacturer with recipients all around the world, we at Cochlear understand our responsibility to innovate reliable implants and upgradeable sound processors that meet the needs of our customers today and in the future,” said Patricia Trautwein, AuD, Vice President, Marketing and Product Management, Cochlear Americas. “In addition, our commitment extends beyond the product portfolios to include service innovations being realized with future-thinking connectivity that are transforming hearing healthcare.”

The Nucleus Profile Plus Series Cochlear Implant will be commercially available later this month. The Nucleus Profile Plus Series Cochlear Implant is still awaiting approval by Health Canada. For more detailed information on the portfolio of Cochlear Nucleus Implants’ MRI compatibility, visit:

The Nucleus 7 Sound Processor expanded connectivity features will be commercially available this fall across the US and Canada through a simple firmware update.

Source: Cochlear

Images: Cochlear 


  1. MRI Guidelines D774756.

  2. Cochlear Nucleus Implant Reliability Report. Volume 17 | December 2018. D1593476. Cochlear Ltd; 2019.

  3. Hearing Implant Reliability Reporting | MED-EL [Internet]. 2018 [cited 06May2019]. Available from:

  4. 2018 Global Implant Reliability Report. 027-N025-02. Advanced Bionics AG and affiliates.; 2019.

  5. Data on File: Internal Specifications

  6. Cochlear Limited. D1190805. CP1000 Processor Size Comparison. 2019, Apr; Data on file.

  7. Cochlear Limited. D1140877. Battery Life and Power Consumption Comparison between CP1000, CP900 Series and CP810 Sound Processors. 2017, Sept; Data on file.

  8. Apple Inc. ‘Compatible hearing devices’ [Internet]. Apple support. 2018 [cited 10 May 2019]. Available from:

* For more detailed information on sound processor and app compatibility, visit